Drug profile

The FDA adverse-event record for Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage)

Name: Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) - FDA Animal Adverse Event Reports
Creator: PlainBreed
License: https://creativecommons.org/publicdomain/zero/1.0/

89 FDA reports name Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage), a high-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#822 of 2,679
by report volume (all drugs): 89
adverse-event reports: 97.8%
death-coded share: Fish
most-reported species

Compiled by PlainBreed

Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 of 1130 drugs with at least 50 reports by highest death-coded share (97.8%) at report rank #821 of 2679; separately, Milbemycin Oxime + Spinosad is #1 by total reports at 149,624 (death-coded-share rank 965).

149,624
Milbemycin Oxime + Spinosad reports (#1): 97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1): #821
This drug, reports of 2679: #1
This drug, death share of 1130

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) has 89 reports now versus 89 in that prior snapshot: 0 the same number of (0.0%).

Report change: +0
Death-coded reports: +0
Death-coded share: +0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) changes

Signature read: Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage)'s 97.8% death-coded share is among the highest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.

Total Reports

Deaths Reported

97.8%

Death-coded share of reports

Active Ingredients

Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage)

Administration Routes

Unknown

Species Affected

Fish 88

Unknown 1

Most Affected Breeds

Atlantic Salmon (Salmo salar) 88

Unknown 1

Most Reported Reactions

Death 63

IGA Animal mortality greater than expected 35

Fish body deformity 28

Moribund 24

IGA Animal morbidity greater than expected 17

Death by euthanasia 14

Partial lack of efficacy 2

Product Defect, General 2

Genotypic test failure (IGA) 2

Unrelated death 1

Fungal skin infection NOS 1

Containment system or component failure (IGA) 1

Outcome Breakdown

Died

63 (59.4%)

Euthanized

39 (36.8%)

Ongoing

4 (3.8%)

Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage): high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

High-volume nationwide drug peers

Two openFDA-derived peer sets for Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage), both floored at ≥50 reports so the neighborhoods stay in the advertised mass.

Similar report volume

Nearest other drugs by FDA report count (89 here).

Amoxicillin Trihydrate/Clavulanic Acid 89 Cbd Oil 89 Tris-Edta 89 Unspecified Ear Cleaner 89

Similar death-coded share

Nearest other drugs by death-coded share (97.8% here), distinct from the volume row.

Bovine Parainfluenza 3, Pi3 Ebk-1/Ebht-1 Strain Al-Im;Bovine Respiratory Syncyti 92.9% Bovine Viral Diarrhea Virus, Type 1, Strain Nadl-Sbvd, Msvx+1;Bovine Viral Diarr 92.4% Ibr / Pi3 (Orig S-P Us) Lv 92.2% Bovine Viral Diarrhea Virus, Type 2, Strain 53637, Lot Bvd2Mlv-D;Bovine Viral Di 91.9%

What to do with this drug

Compare Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage)'s report volume and death-coded share against similar drugs nationwide. See similar drugs
Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
Browse the full drug directory to compare report counts across products. All drugs

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) (#822 of 2,679 by report volume); death-coded 97.8%. PlainBreed drug row · death-coded share stamp 97.8% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →